Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

Intellia Therapeutics stock soars on promising Phase 3 results for its hereditary angioedema (HAE) candidate. But is there ...

The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

Intellia Therapeutics’ in vivo CRISPR therapy, lonvo-z, met its primary goal in a Phase III hereditary angioedema trial, cutting attacks by 87% versus placebo. All treated patients avoided long-term ...

The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial ...

Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...

Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news ...

Intellia Therapeutics’ in vivo CRISPR gene therapy, lonvo-z, significantly reduced hereditary angioedema attacks in a Phase III trial, meeting its primary endpoint. Patients receiving the one-time ...

A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.

Qatar has taken a landmark step in precision medicine after Sidra Medicine became the first hospital in the country — and one ...